Hengehold Capital Management’s AbbVie ABBV Stock Holding History

Hengehold Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.15M	Buy	28,404 +643	+2%	+$138K	0.55%	39
2026 Q1	$6.04M	Sell	27,761 -100	-0.4%	-$22.2K	0.53%	42
2025 Q4	$6.37M	Buy	27,861 +470	+2%	+$107K	0.54%	41
2025 Q3	$6.34M	Buy	27,391 +751	+3%	+$153K	0.54%	39
2025 Q2	$4.95M	Buy	26,640 +121	+0.5%	+$22.5K	0.45%	47
2025 Q1	$5.56M	Buy	26,519 +36	+0.1%	+$7K	0.53%	37
2024 Q4	$4.71M	Buy	26,483 +86	+0.3%	+$15.8K	0.44%	46
2024 Q3	$5.21M	Buy	26,397 +479	+2%	+$89.4K	0.49%	41
2024 Q2	$4.45M	Buy	25,918 +505	+2%	+$83.7K	0.46%	45
2024 Q1	$4.63M	Sell	25,413 -227	-0.9%	-$39.1K	0.49%	43
2023 Q4	$3.97M	Buy	25,640 +264	+1%	+$38.5K	0.47%	44
2023 Q3	$3.78M	Sell	25,376 -460	-2%	-$67.5K	0.49%	41
2023 Q2	$3.48M	Sell	25,836 -181	-0.7%	-$26.5K	0.46%	43
2023 Q1	$4.15M	Buy	26,017 +41	+0.2%	+$6.27K	0.57%	38
2022 Q4	$4.2M	Buy	25,976 +1,590	+7%	+$244K	0.58%	37
2022 Q3	$3.27M	Buy	24,386 +353	+1%	+$50.7K	0.5%	36
2022 Q2	$3.68M	Buy	24,033 +440	+2%	+$67.2K	0.52%	32
2022 Q1	$3.83M	Sell	23,593 -155	-0.7%	-$22.5K	0.52%	32
2021 Q4	$3.21M	Buy	23,748 +95	+0.4%	+$11.2K	0.4%	35
2021 Q3	$2.55M	Buy	23,653 +390	+2%	+$44.6K	0.34%	45
2021 Q2	$2.62M	Buy	23,263 +366	+2%	+$41.2K	0.34%	44
2021 Q1	$2.48M	Sell	22,897 -434	-2%	-$46.4K	0.34%	46
2020 Q4	$2.5M	Buy	23,331 +609	+3%	+$58.5K	0.37%	35
2020 Q3	$1.99M	Sell	22,722 -225	-1%	-$21.2K	0.32%	45
2020 Q2	$2.25M	Sell	22,947 -139	-0.6%	-$12.2K	0.4%	35
2020 Q1	$1.76M	Sell	23,086 -7,573	-25%	-$645K	0.38%	36
2019 Q4	$2.71M	Buy	30,659 +589	+2%	+$48.9K	0.46%	34
2019 Q3	$2.28M	Buy	30,070 +1,681	+6%	+$115K	0.42%	41
2019 Q2	$2.06M	Buy	28,389 +299	+1%	+$23.5K	0.4%	47
2019 Q1	$2.26M	Buy	28,090 +1,412	+5%	+$116K	0.53%	39
2018 Q4	$2.46M	Buy	26,678 +1,505	+6%	+$132K	0.79%	29
2018 Q3	$2.38M	Buy	25,173 +650	+3%	+$61.6K	0.6%	34
2018 Q2	$2.27M	Sell	24,523 -156	-0.6%	-$15.2K	0.59%	35
2018 Q1	$2.34M	Sell	24,679 -363	-1%	-$39.9K	0.61%	33
2017 Q4	$2.42M	Sell	25,042 -10,951	-30%	-$1.03M	0.64%	34
2017 Q3	$3.2M	Buy	35,993 +302	+0.8%	+$23K	0.85%	24
2017 Q2	$2.59M	Buy	35,691 +671	+2%	+$45.1K	0.73%	24
2017 Q1	$2.28M	Buy	35,020 +1,613	+5%	+$101K	0.63%	31
2016 Q4	$2.09M	Buy	33,407 +2,152	+7%	+$131K	0.64%	34
2016 Q3	$1.97M	Buy	31,255 +169	+0.5%	+$10.9K	0.63%	30
2016 Q2	$1.93M	Buy	31,086 +95	+0.3%	+$5.79K	0.63%	31
2016 Q1	$1.77M	Buy	+30,991	New	+$1.73M	0.57%	40

Other funds holding ABBV

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

ECSS

Eurizon Capital SGR SpA Milan $37.3B AUM

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Hengehold Capital Management's ABBV Position: Q2 2026 in Review

Hengehold Capital Management increased its AbbVie (ABBV) stake by 2.3% in Q2 2026, buying an estimated $138K and bringing the position to 28,404 shares worth $7.15M. The position accounts for 0.55% of the portfolio, ranked #39.

Hengehold Capital Management first reported a position in ABBV in Q1 2016 and has held it in 42 quarters since. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Hengehold Capital Management held 28,404 shares of AbbVie worth $7.15M as of Q2 2026.
Hengehold Capital Management bought 643 AbbVie shares in Q2 2026, an estimated $138K.
AbbVie made up 0.55% of Hengehold Capital Management's portfolio in Q2 2026, its #39 holding.
Hengehold Capital Management first reported a position in AbbVie in Q1 2016 and has held it in 42 quarters since.
2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Hengehold Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.